Increased Expression of P-Glycoprotein and Doxorubicin Chemoresistance of Metastatic Breast Cancer Is Regulated by miR-298

被引:250
作者
Bao, Lili [1 ]
Hazari, Sidhartha [1 ]
Mehra, Smriti [2 ]
Kaushal, Deepak [2 ]
Moroz, Krzysztof [1 ]
Dash, Srikanta [1 ]
机构
[1] Tulane Univ, Hlth Sci Ctr, Dept Pathol & Lab Med, New Orleans, LA 70112 USA
[2] Tulane Natl Primate Res Ctr, Covington, LA USA
关键词
RESISTANCE MDR1 GENE; MULTIDRUG-RESISTANCE; TRANSCRIPTIONAL ACTIVATION; MICROPROCESSOR COMPLEX; DRUG-RESISTANCE; NUCLEAR EXPORT; CELLS; MICRORNAS; PROTEIN; TRANSPORTERS;
D O I
10.1016/j.ajpath.2012.02.024
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
MicroRNAs (miRNAs) are short, noncoding RNA molecules that regulate the expression of a number of genes involved in cancer; therefore, they offer great diagnostic and therapeutic targets. We have developed doxorubicin-resistant and -sensitive metastatic human breast cancer cell lines (MDA-MB-231) to study the chemoresistant mechanisms regulated by miRNAs. We found that doxorubicin localized exclusively to the cytoplasm and was unable to reach the nuclei of resistant tumor cells because of the increased nuclear expression of MDR1/P-glycoprotein (P-gp). An miRNA array between doxorubicin-sensitive and -resistant breast cancer cells showed that reduced expression of miR-298 in doxorubicin-resistant human breast cancer cells was associated with increased expression of P-gp. In a transient transfection experiment, miR-298 directly bound to the MDR1 3' untranslated region and regulated the expression of firefly luciferase reporter in a dose-dependent manner. Overexpression of miR-298 down-regulated P-gp expression, increasing nuclear accumulation of doxorubicin and cytotoxicity in doxorubicin-resistant breast cancer cells. Furthermore, down-regulation of miR-298 increased P-gp expression and induced doxorubicin resistance in sensitive breast cancer cells. In summary, these results suggest that naiR-298 directly modulates P-gp expression and is associated with the chemoresistant mechanisms of metastatic human breast cancer. Therefore, miR-298 has diagnostic and therapeutic potential for predicting doxorubicin chemoresistance In human breast cancer. (Am J Pathol 2012, 180:2490-2503; http://dx.doi.org/10.1016/j.ajpath.2012.02.024)
引用
收藏
页码:2490 / 2503
页数:14
相关论文
共 40 条
  • [1] Abolhoda A, 1999, CLIN CANCER RES, V5, P3352
  • [2] Resistance May Not Be Futile: microRNA Biomarkers for Chemoresistance and Potential Therapeutics
    Allen, Kristi E.
    Weiss, Glen J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2010, 9 (12) : 3126 - 3136
  • [3] Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene
    Bailey-Dell, KJ
    Hassel, B
    Doyle, LA
    Ross, DD
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2001, 1520 (03): : 234 - 241
  • [4] Increased Expression of P-Glycoprotein Is Associated with Doxorubicin Chemoresistance in the Metastatic 4T1 Breast Cancer Model
    Bao, Lili
    Haque, Aliyya
    Jackson, Kamilah
    Hazari, Sidhartha
    Moroz, Krzysztof
    Jetly, Rachna
    Dash, Srikanta
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2011, 178 (02) : 838 - 852
  • [5] PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-κB
    Bark, H.
    Choi, Cheol-Hee
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (06) : 1131 - 1136
  • [6] The microRNA.org resource: targets and expression
    Betel, Doron
    Wilson, Manda
    Gabow, Aaron
    Marks, Debora S.
    Sander, Chris
    [J]. NUCLEIC ACIDS RESEARCH, 2008, 36 : D149 - D153
  • [7] INDUCTION OF MULTIDRUG RESISTANCE IN HUMAN-CELLS BY TRANSIENT EXPOSURE TO DIFFERENT CHEMOTHERAPEUTIC DRUGS
    CHAUDHARY, PM
    RONINSON, IB
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (08) : 632 - 639
  • [8] CHIN KV, 1990, J BIOL CHEM, V265, P221
  • [9] CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361
  • [10] Dean M, 2001, J LIPID RES, V42, P1007